Get the Stockscreener App
185.20
0.79%
-1.48
Pre-market:
188.39
3.19
+1.72%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca Plc stock is traded at $185.20, with a volume of 4.42M.
It is down -0.79% in the last 24 hours and down -1.71% over the past month.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
See More
Previous Close:
$186.68
Open:
$183.93
24h Volume:
4.42M
Relative Volume:
1.79
Market Cap:
$287.21B
Revenue:
$58.80B
Net Income/Loss:
$10.24B
P/E Ratio:
56.48
EPS:
3.2788
Net Cash Flow:
$8.98B
1W Performance:
-4.93%
1M Performance:
-1.71%
6M Performance:
+125.22%
1Y Performance:
+158.26%
1-Day Range:
$181.73
$187.00
1-Week Range:
$181.73
$196.64
52-Week Range:
$66.16
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Name
Astrazeneca Plc
Sector
Industry
Phone
-
Address
-
Compare AZN vs LLY, JNJ, ABBV, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
185.20 | 289.51B | 58.80B | 10.24B | 8.98B | 3.2788 |
LLY
Lilly Eli Co
|
851.21 | 780.79B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
227.35 | 548.34B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
203.89 | 349.67B | 62.82B | 3.62B | 17.82B | 2.0331 |
MRK
Merck Co Inc
|
110.95 | 271.76B | 64.93B | 18.26B | 12.36B | 7.2751 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Buy |
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca Plc Stock (AZN) Latest News
Citi raises AstraZeneca earnings forecast and maintains 'buy' rating ahead of second-half pipeline catalysts - Proactive Investors
Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca - Quantisnow
Astrazeneca injects £300m into UK sites - marketscreener.com
Astrazeneca Q1 Earnings Call Highlights - Yahoo Finance
AstraZeneca takes global rights to an EGFR cancer drug in $25M deal - Stock Titan
AstraZeneca CEO says US MFN policy will have substantial impact on European drug launches, pricing - marketscreener.com
IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight - GlobeNewswire Inc.
Correction to AstraZeneca Update - marketscreener.com
AstraZeneca Q1 2026 slides: pipeline delivers, revenue reporting raises questions - Investing.com
AstraZeneca plans to invest $405 million in Britain, PM Starmer says - marketscreener.com
AstraZeneca beats Q1 estimates, CEO says drug pipeline is 'delivering' - Yahoo Finance
AstraZeneca to make $405 million investment in Britain, PM Starmer says - marketscreener.com
AstraZeneca: Q1 Earnings Analysis: An Excellent Long-Term Buy And Hold (NYSE:AZN) - Seeking Alpha
What's Going On With AstraZeneca Stock Wednesday?AstraZeneca (NYSE:AZN) - Benzinga
AstraZeneca PLC 2026 Q1ResultsEarnings Call Presentation (NYSE:AZN) 2026-04-29 - Seeking Alpha
AstraZeneca revives Cambridge investment after UK agrees to pay more for drugs - Financial Times
Astrazeneca (AZN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
AstraZeneca to inject £300 million into UK in surprise U-turn - Yahoo Finance UK
AstraZeneca to Invest £300 Million in UK in Boost for Starmer - Bloomberg
AstraZeneca: Desirable start to 2026, but most strengths are already priced in - marketscreener.com
AstraZeneca Plans to Invest $406 Million in U.K. - marketscreener.com
ASTRAZENECA : From Neutral to Buy by DZ Bank - marketscreener.com
Starmer: AstraZeneca to invest £300M in UK - Breakingthenews.net
BofA Maintains AstraZeneca at Buy After Q1 Sales Beat - marketscreener.com
What next for AstraZeneca shares, after another cracking quarter? - Fool UK
UK PM Starmer: AstraZeneca to invest 300 mln pound in UK - marketscreener.com
AstraZeneca (NYSE: AZN) posts Q1 2026 growth and major pipeline deals - Stock Titan
Shot in the arm for GSK and AstraZeneca from cancer drug sales - Yahoo Finance UK
AstraZeneca posts $15.3B sales after 14 approvals in major regions - Stock Titan
Why AstraZeneca (AZN) Stock Fell Despite Crushing Q1 Earnings Expectations - Blockonomi
ASTRAZENECA : From Neutral to Buy by Barclays - marketscreener.com
AstraZeneca’s Profit Climbs on Strong Sales of Cancer Drugs - Bloomberg
FTSE 100 Pharma Strength As AstraZeneca Drives Momentum - Kalkine Media
AstraZeneca PLC Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
AstraZeneca backs outlook as first quarter sales and profit beat hopes - London South East
AstraZeneca PLC reports results for the quarter ended December 31Earnings Summary - TradingView
-1.23% for AstraZeneca stock amid US FDA scrutiny of camizestrant and Truqap - Traders Union
AstraZeneca Reports Robust Q1 Growth and Advances High-Value Drug Pipeline - Yahoo Finance UK
AstraZeneca Q1 Core Earnings, Revenue Rise; Reiterates 2026 Guidance - marketscreener.com
AstraZeneca sticks to its guns after strong first-quarter revenue growth - Proactive Investors
AstraZeneca, Lloyds, GSK post first-quarter growth - marketscreener.com
AstraZeneca tops Q1 forecasts on strong cancer, rare-disease drug demand - Investing.com Nigeria
AstraZeneca PLC Ordinary Shares (AZN.US) 1Q Core EPS Beats Forecast, Reaffirms Full-Year Revenue and Earnings Guidance - AASTOCKS.com
AstraZeneca, GSK profit rises on strong sales of crucial cancer drugs - CNBC TV18
AstraZeneca reconfirms total revenue & core EPS guidance for 2026 - marketscreener.com
Astrazeneca: Q1 Earnings Snapshot - marketscreener.com
AstraZeneca Q1 revenues grow, reiterates FY26 constant currency guidance - Sharecast.com
AstraZeneca beats profit expectations, keeps annual outlook unchanged - marketscreener.com
AstraZeneca Gets Revenue Boost From Cancer Drugs - marketscreener.com
AstraZeneca's Q1 revenue tops estimates at $15.3B, up 8% - Breakingthenews.net
Earnings Flash (AZN.L) AstraZeneca Posts Q1 EPS $1.97 - marketscreener.com
Astrazeneca Plc Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
1.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):